Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Gaviscon Peppermint Flavour Tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Calcium carbonate, Sodium alginate, Sodium hydrogen carbonate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
How to take it
Gaviscon Peppermint Flavour Tablets: For oral administration. Chew thoroughly before swallowing. Adults, including the elderly and children 12 years and over: When symptoms occur take two to four tablets after meals and at bedtime. Children under 12 years: Should only be taken on medical advice. If you forget a dose, it is not necessary to double the dose next time, just carry on taking as before. If you take too much of this product you may feel bloated and experience some abdominal discomfort. It is unlikely to cause you any harm, but please consult your doctor or pharmacist. After taking Gaviscon Peppermint Flavour Tablets: If symptoms persist after 7 days consult your doctor.
Possible side effects
: Very rare (less than 1 in 10,000) chance of an allergic reaction to the ingredients. Symptoms of this may include skin rash, itching, difficulty breathing, dizziness, or swelling of the face, lips, tongue or throat. If you experience these or any other side-effects stop taking the product and consult your doctor immediately. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: "http://www.mhra.gov.uk/yellowcard" or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. Storing your medicine: Do not use this product after the expiry date (EXP: month/year) shown KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Do not store above 30°C. Further information Gaviscon Peppermint Flavour Tablets are circular tablets with an off white to cream, slightly mottled appearance. Each chewable tablet contains 250mg sodium alginate, 133.5mg sodium hydrogen carbonate and 80mg calcium carbonate as the active ingredients. The other ingredients are mannitol (E421), macrogol 20,000, copovidone, aspartame (E951), peppermint flavouring, magnesium stearate and acesulfame potassium. These tablets do not contain sugar or gluten. Gaviscon Peppermint Flavour Tablets are available in pack sizes of 6's, 8's, 12's, 16's, 24's, 32's, & 48's. Not all pack sizes may be marketed. Manufacturer and PL Holder in UK: Reckitt Benckiser Healthcare (UK) Ltd., Hull, HU8 7DS. Gaviscon and are trade marks. PL 00063/0627 Date of Preparation: February 2021
CUSTOMER INFO: Minimum Point Size = 9.00pt
250mg Tablets
Segment:
Peppermint
Pack Size:
12Tablets UK
Pharmacode Reads This Way
Date:
12/02/21
RBH Contact:
Anoop James
Last Bar
Artwork Type: BW Submission
First Bar
220
Market/Country:
2nd Component Code (if applicable):
0000000 N/A
Parent Technical Packaging Specification:
D0260665
Finished Goods Code:
0000000
Supply Point:
RB Hull
3rd Party Code
N/A
Pharmacode No/NE:
N/A
Component Code (2D if applicable):
Edgemark Position:
N/A
CAD Cam Ref:
G-Lflt-D0260665-100x175mm
Printer:
Medica Packaging Limited (Crewe, UK)
Substrate:
Paper White
Technical & Non Printing Items Cutter
Cutter 2 (if applicable)
Guides
Guides 2 (if applicable)
210
Adult
Segment Group:
230
Gaviscon
Category:
200
D
190
TR2081951
Action: Brand:
31mm 6mm 13mm 6mm
RB453952
ZEN Ref:
180
5 mm
Trident Reference No:
240 250
RB Artwork and Print Specification
170
175 mm
PATIENT INFORMATION LEAFLET GAVISCON PEPPERMINT FLAVOUR TABLETS Sodium alginate Sodium hydrogen carbonate Calcium carbonate Please read this leaflet carefully before you take this medicine. If you are not sure about anything ask your pharmacist or doctor What are Gaviscon Peppermint Flavour Tablets? Gaviscon Peppermint Flavour Tablets belong to a group of medicines called "reflux suppressants", which form a protective layer on top of the stomach contents to prevent stomach acid escaping from the stomach where it works into the food pipe causing pain and discomfort. What are Gaviscon Peppermint Flavour Tablets used for? Gaviscon Peppermint Flavour Tablets are used for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux) which may occur, for example, following meals or during pregnancy, and in patients with symptoms related to oesophagitis. Before taking Gaviscon Peppermint Flavour Tablets: Do not take this product if:
- you know you are allergic to any of the ingredients as very rarely difficulty in breathing and skin rashes have occurred (see further information for a full list of ingredients). Take special care before treatment with Gaviscon Peppermint Flavour Tablets: This medicine contains 11 mmol of sodium (253 mg) and 3.2 mmol of calcium per 4 tablet dose.
- If you have been advised to follow a diet restricted in either of these salts please consult your doctor before taking this product.
- The maximum recommended daily dose of this medicinal product contains 1012 mg sodium (found in table salt). This is equivalent to 50.6% of the adult recommended maximum daily dietary intake for sodium. Talk to your doctor or pharmacist if you need this product on a daily basis for a prolonged period, especially if you have been advised to follow a low salt diet.
- Please also talk to your doctor regarding these salt contents if you suffer or have suffered from significant kidney or heart disease, as certain salts could interfere with these diseases. This medicine contains 3.75 mg aspartame in each tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly Taking other medicines: Do not take this product within two hours of taking other medicines by mouth as it can interfere with the action of some other medicines. This is especially important if you are taking antibiotics (tetracyclines and quinolones such as orfloxacin), iron preparation, antifungals such as ketoconazole, digoxin and beta blockers (for heart conditions), penicillamine (commonly for rheumatoid arthritis), glucocorticoid (for inflammatory and autoimmune disorders), neuroleptics (for mental illness), thyroid hormones, chloroquine (for malaria), estramustine (for prostate cancer) and biphosphonates (for osteoporosis).
Colours (Leaflet)
160
Process Black
N/A
Barcode Number:
N/A
Magnification:
N/A N/A
Full Height:
N/A
Bar Height (Smallest Bar):
N/A
BWR:
N/A
Encoded Data:
N/A
UNDER NO CIRCUMSTANCES SHOULD THIS ARTWORK BE ALTERED WITHOUT PRIOR PERMISSION FROM TRIDENT.
1.3.1 Package Leaflet – Proposed Gaviscon Peppermint Tablets National 0007239 eCTD
Page 1
STUDIO USE ONLY
Muthukumar Rajachithambaram v2.0
Sm•Art check results:
G=2; O=0; R=0; – MR – 12/02/21 15:25:07
30 20
Please note that any low resolution paper Canon colour copies associated with this job should be referred to for content, layout and colour separation only.
mm 10
Connaught House, Connaught Road, Kingswood Business Park, Hull, HU7 3AP, England. T: +44 (0) 1482 828100
40
50
60
70
80
Truncated By:
100
Barcode Type:
90
BARCODE INFO
110
120
130
140
150
1 LTH
Frequently asked questions about Gaviscon Peppermint Flavour Tablets
How do I take Gaviscon Peppermint Flavour Tablets?
Gaviscon Peppermint Flavour Tablets comes as tablet. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Gaviscon Peppermint Flavour Tablets?
The active substance in Gaviscon Peppermint Flavour Tablets is calcium carbonate, sodium alginate, sodium hydrogen carbonate.
Are there equivalent medicines to Gaviscon Peppermint Flavour Tablets?
Medicines with the same active substance, strength and form include: Gaviscon Double Action Mixed Berries Flavour Chewable Tablets. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Gaviscon Peppermint Flavour Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Gaviscon Peppermint Flavour Tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: calcium carbonate, sodium alginate, sodium hydrogen carbonate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.
4.2. Posology and method of administration
For oral use, after being thoroughly chewed.
Adults and children 12 years and over: Two to four tablets after meals and at bedtime.
Elderly: No dose modifications necessary for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary (see section 4.4).
4.3. Contraindications
This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.
4.4. Special warnings and precautions for use
If symptoms do not improve after 7 days, the clinical situation should be reviewed.
This medicinal product contains 235 mg (11 mmol) of sodium per four-tablet dose, equivalent to 12.65% of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is equivalent to 50.6% of the WHO recommended maximum daily intake for sodium. This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment).
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Due to its aspartame content this product should not be given to patients with phenylketonuria.
4.5. Interaction with other medicinal products and other forms of interaction
A time-interval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine, biphosphonates (diphosphonates) and estramustine. See also 4.4.
4.6. Fertility, pregnancy and lactation
Pregnancy:
Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor feto/ neonatal toxicity of the active substances.
Gaviscon can be used during pregnancy, if clinically needed.
Breast feeding:
No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. Gaviscon can be used during breast-feeding.
Fertility:
There is a lack of robust pre-clinical data available regarding the effects of alginate on fertility; limited studies have not reported any negative effects on parental or offspring fertility or reproduction.
Clinical data do not suggest that Gaviscon has an effect on human fertility.
4.7. Effects on ability to drive and use machines
Not relevant.
4.8. Undesirable effects
Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Event
Immune System Disorders
Very rare
Anaphylactic and anaphylactoid reactions.
Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders
Very rare
Respiratory effects such as bronchospasm.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Symptoms
Symptoms are likely to be minor; some abdominal discomfort may be experienced.
Management
In the event of overdose symptomatic treatment should be given.
💬 Ask about this leaflet
Ask anything about Gaviscon Peppermint Flavour Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.